BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

EpiVax Adds AI-Enabled Enhancements to ISPRI Immunogenicity Risk Platform

EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the ...

September 04, 2026 | News

Everest Medicines Secures China Approval for CARDAMYST to Treat Acute PSVT Episodes

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

September 04, 2026 | News

IDT and Ansa Expand Global Access to Complex DNA Synthesis Through Integrated Ordering

Streamlined workflow provides earlier visibility into synthesis feasibility, pricing, and fulfillment options Global adoption growing with more than 400...

September 03, 2026 | News

Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis

Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...

September 03, 2026 | News

Singapore Becomes First ASEAN Market to Subsidise Vutrisiran for ATTR Amyloidosis

"From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75%[1],[2]" "HELIOS-A and B provide strong ...

September 02, 2026 | News

Convergen Raises $15M Seed+ to Accelerate Targeted Protein Degradation Therapies

Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, an...

September 02, 2026 | News

Astellas Reaches US Government Agreement to Lower Medicaid Drug Prices, Strengthen Medicine Supply Chain

Agreement supports commitment to patient access, affordability and innovation – Astellas Pharma Inc. announced that it has reached an agreemen...

September 02, 2026 | News

ReviR Therapeutics’ RTX-117 Secures FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth Disease

Designation supports the global development of RTX-117 and may provide potential future access to a transferable Priority Review Voucher, subject to approv...

August 28, 2026 | News

US FDA Approves BeOne’s TEVIMBRA-ZIIHERA Combination for First-Line HER2+ Gastroesophageal Cancer

TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ ...

August 27, 2026 | News

Antengene’s ATG-201 Wins Australian Clearance for Phase I Autoimmune Disease Trial

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

August 26, 2026 | News

Pulnovo Medical Enrols First Patients in PULSE-LHD Trial for Pulmonary Hypertension

Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), announced the enrollment of the f...

August 24, 2026 | News

South Korea’s Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech in $2.3B Deal

HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including ob...

August 25, 2026 | News

CureGene Doses First Subject in Australia Phase I Trial of Oral Metabolic Drug CG-0416

CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist...

August 24, 2026 | News

US FDA Grants Breakthrough Therapy and Fast Track Designations to NORROY’s 68Ga-NYM096 for Kidney Cancer Imaging

NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food ...

August 21, 2026 | News

Stay Connected